Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Abstract Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV...

Full description

Bibliographic Details
Main Authors: Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Subcutaneous semaglutide
Oral semaglutide
Cardiovascular
MACE
SUSTAIN
Online Access:http://link.springer.com/article/10.1186/s12933-020-01106-4

Internet

http://link.springer.com/article/10.1186/s12933-020-01106-4

Similar Items